New agents in intravesical chemotherapy of superficial bladder cancer

Perabo, Frank; Müller, Stefan

doi:10.1080/00365590510007676

Cited by 21 publications

(10 citation statements)

References 30 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suramin is also a potent inhibitor of SIRT1 (IC 50 =0.297 μM) and SIRT2 (IC 50 = 1.15 μM) (105). Suramin is a polyanionic naphthylurea that was originally used for the treatment of trypanosomiasis, but also shows antiproliferative and antiviral activity (106). …”

Section: Sirtuin Inhibitorsmentioning

confidence: 99%

Sirtuin activators and inhibitors

2012

View full text Add to dashboard Cite

Sirtuins 1-7 (SIRT1-7) belong to the third class of deacetylase enzymes, which are dependent on NAD+ for activity. Sirtuins activity is linked to gene repression, metabolic control, apoptosis and cell survival, DNA repair, development, inflammation, neuroprotection and healthy aging. Because sirtuins modulation could have beneficial effects on human diseases there is a growing interest in the discovery of small molecules modifying their activity. We review here those compounds known to activate or inhibit sirtuins, discussing the data that support the use of sirtuin-based therapies. Almost all sirtuin activators have been described only for SIRT1. Resveratrol is a natural compound which activates SIRT1, and may help in the treatment or prevention of obesity, and in preventing tumorigenesis and the aging-related decline in heart function and neuronal loss. Due to its poor bioavailability, reformulated versions of resveratrol with improved bioavailability have been developed (resVida, Longevinex®, SRT501). Molecules that are structurally unrelated to resveratrol (SRT1720, SRT2104, SRT2379, among others) have been also developed to stimulate sirtuin activities more potently than resveratrol. Sirtuin inhibitors with a wide range of core structures have been identified for SIRT1, SIRT2, SIRT3 and SIRT5 (splitomicin, sirtinol, AGK2, cambinol, suramin, tenovin, salermide, among others). SIRT1 inhibition has been proposed in the treatment of cancer, immunodeficiency virus infections, Fragile X mental retardation syndrome and for preventing or treating parasitic diseases, whereas SIRT2 inhibitors might be useful for the treatment of cancer and neurodegenerative diseases.

show abstract

Section: Sirtuin Inhibitorsmentioning

confidence: 99%

Sirtuin activators and inhibitors

2012

View full text Add to dashboard Cite

show abstract

“…At certain concentrations, GLA exhibits anti-tumour activity by inhibiting the growth and metastasis of a variety of tumour cells, including prostate [6], breast [7,8], superficial bladder [9,10] and pancreatic [11] cancer, as well as human gliomas [12,13]. GLA attenuates prostate carcinogenesis via the generation of 15-hydroxyeicosatrienoic acid [14] and also reduces cancer cell adhesion and cell motility by decreasing secretion of osteonectin [15].…”

Section: Introductionmentioning

confidence: 99%

LC/ESR/MS study of spin trapped carbon-centred radicals formed fromin vitrolipoxygenase-catalysed peroxidation ofγ-linolenic acid

Zhang

et al. 2008

Free Radical Research

View full text Add to dashboard Cite

Abstractγ-Linolenic acid (GLA) has been reported as a potential anti-cancer and anti-inflammatory agent and has received substantial attention in cancer care research. One of the many proposed mechanisms for GLA biological activity is free radical-mediated lipid peroxidation. However, no direct evidence has been obtained for the formation of GLA-derived radicals. In this study, a combination of LC/ ESR and LC/MS was used with α-[4-pyridyl-1-oxide]-N-tert-butyl nitrone (POBN) to profile the carbon-centred radicals that are generated in lipoxygenase-catalysed GLA peroxidation. A total of four classes of GLA-derived radicals were characterized including GLA-alkyl, epoxyallylic, dihydroxyallylic radicals and a variety of carbon-centred radicals stemming from the β-scissions of GLA-alkoxyl radicals. By means of an internal standard in LC/MS, one also quantified each radical adduct in all its redox forms, including an ESR-active form and two ESR-silent forms. The results provided a good starting point for ongoing research in defining the possible biological effects of radicals generated from GLA peroxidation.

show abstract

“…Considerable interest has been growing with the use of gemcitabine as an intravesical agent for superficial bladder cancer [31][32][33][34][35][36][37]. Most studies focused on its potential use in a second-line setting after failing primary therapy with BCG.…”

Section: Intravesical Therapymentioning

confidence: 99%

Bladder cancer

Gwynn

Clark

2006

Current Opinion in Oncology

View full text Add to dashboard Cite

The detection of bladder cancer continues to rely on direct visualization with cystoscopy. Efforts are underway to improve the utility of urinary markers and cystoscopy through fluorescence endoscopy. The management of superficial bladder cancer is based on transurethral resection of the tumor with perioperative intravesical instillation of chemotherapy strongly suggested for most patients. Risk stratifying patients with high-risk superficial bladder cancer remain a challenge and area of future research.

show abstract

New agents in intravesical chemotherapy of superficial bladder cancer

Cited by 21 publications

References 30 publications

Sirtuin activators and inhibitors

Sirtuin activators and inhibitors

LC/ESR/MS study of spin trapped carbon-centred radicals formed fromin vitrolipoxygenase-catalysed peroxidation ofγ-linolenic acid

Bladder cancer

Contact Info

Product

Resources

About